Media headlines about Sucampo Pharmaceuticals (NASDAQ:SCMP) have been trending somewhat positive on Monday, according to Accern Sentiment. Accern rates the sentiment of press coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Sucampo Pharmaceuticals earned a coverage optimism score of 0.13 on Accern’s scale. Accern also assigned media coverage about the biopharmaceutical company an impact score of 45.7593416151527 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.

Here are some of the news headlines that may have impacted Accern Sentiment Analysis’s analysis:

Shares of Sucampo Pharmaceuticals (NASDAQ SCMP) opened at $12.80 on Monday. Sucampo Pharmaceuticals has a 12 month low of $9.30 and a 12 month high of $17.24. The company has a market capitalization of $596.94, a PE ratio of 8.77, a PEG ratio of 3.81 and a beta of 1.46. The company has a debt-to-equity ratio of 7.37, a quick ratio of 4.46 and a current ratio of 5.11.

Sucampo Pharmaceuticals (NASDAQ:SCMP) last announced its quarterly earnings results on Wednesday, November 1st. The biopharmaceutical company reported $0.27 EPS for the quarter, beating the Zacks’ consensus estimate of $0.25 by $0.02. Sucampo Pharmaceuticals had a positive return on equity of 74.58% and a negative net margin of 60.24%. The firm had revenue of $61.27 million for the quarter, compared to analyst estimates of $58.05 million. During the same period last year, the firm posted $0.30 earnings per share. The business’s revenue for the quarter was up 5.9% on a year-over-year basis. sell-side analysts anticipate that Sucampo Pharmaceuticals will post 1.12 EPS for the current fiscal year.

SCMP has been the topic of several research analyst reports. initiated coverage on Sucampo Pharmaceuticals in a research note on Wednesday, November 15th. They issued a “buy” rating and a $14.00 price objective on the stock. Zacks Investment Research raised Sucampo Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Tuesday, October 3rd. UBS reduced their price objective on Sucampo Pharmaceuticals from $19.00 to $15.00 and set a “buy” rating on the stock in a research note on Thursday, October 12th. Mizuho reaffirmed a “hold” rating and issued a $12.00 price objective on shares of Sucampo Pharmaceuticals in a research note on Wednesday, November 1st. Finally, Maxim Group reaffirmed a “buy” rating and issued a $23.00 price objective on shares of Sucampo Pharmaceuticals in a research note on Thursday, November 2nd. Three research analysts have rated the stock with a hold rating and nine have given a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $16.00.

In related news, insider Jason Patrick Meyenburg acquired 4,000 shares of the business’s stock in a transaction that occurred on Wednesday, September 6th. The shares were bought at an average cost of $12.13 per share, with a total value of $48,520.00. Following the completion of the purchase, the insider now directly owns 30,228 shares in the company, valued at $366,665.64. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, major shareholder Sachiko Kuno sold 1,000,000 shares of Sucampo Pharmaceuticals stock in a transaction that occurred on Monday, September 11th. The stock was sold at an average price of $12.00, for a total value of $12,000,000.00. The disclosure for this sale can be found here. Company insiders own 4.13% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “Somewhat Positive Media Coverage Somewhat Unlikely to Impact Sucampo Pharmaceuticals (SCMP) Share Price” was first published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this piece of content on another site, it was copied illegally and reposted in violation of US and international copyright and trademark law. The original version of this piece of content can be viewed at https://www.thecerbatgem.com/2017/12/04/somewhat-positive-media-coverage-somewhat-unlikely-to-impact-sucampo-pharmaceuticals-scmp-share-price.html.

About Sucampo Pharmaceuticals

Sucampo Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of pharmaceutical products. Its primary focus areas are gastroenterology, ophthalmology and oncology-related disorders. Its product candidates include VTS-270, Lubiprostone (AMITIZA), Unoprostone is opropyl (RESCULA) and CPP-1X/sulindac combination product.

Insider Buying and Selling by Quarter for Sucampo Pharmaceuticals (NASDAQ:SCMP)

Receive News & Stock Ratings for Sucampo Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sucampo Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.